![https://static.aminer.org/upload/avatar/1145/1482/840/5408b099dabfae44f087d42a.png](https://avatarcdn.aminer.cn/upload/avatar/1145/1482/840/5408b099dabfae44f087d42a.png!160)
Madeleine Duvic
Professor
The University of Texas MD Anderson Cancer Center;Department of Division of Epidemiology
Human Genetics & Environmental Sciences, School of Public Health, The University of Texas;Department of Dermatology, Medical School at Housto, The University of Texas;Division of Internal Medicine, Medical School at Housto, The University of Texas
Follow
Claim
分享
Follow
Claim
分享
基本信息
views: 325
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
My goal is to understand the pathogenesis of T-cell mediated skin diseases in order to develop novel targeted therapy. I have collaborated with pharmacology to develop protocols and then conduct clinical trials that lead to the registration of new FDA approved agents for cutaneous T-cell lymphoma that include bexarotene (first rexinoid), denileukin diftitox (first targeted fusion toxin), and vorinostat (first histone deacetylase inhibitor). In addition to directing an NIH funded molecular biology lab and a clinical trials research team, I personally have cared for over 2,000 MD Anderson cutaneous T-cell lymphoma patients. I belong to the UT graduate school immunology program.
Research Interests
Papers共 754 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Lymphoma Myeloma and Leukemia (2024)
Cellsno. 5 (2024): 419
International journal of dermatology (2024)
American Journal of Clinical Dermatologyno. 2 (2023): 1-17
JAAD international (2023): 55-56
crossref(2023)
International journal of dermatology (2023)
Load More
Author Statistics
#Papers: 751
#Citation: 31436
H-Index: 83
G-Index: 155
Sociability: 8
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn